and prurigo nodularis. Dupilumab is a fully human monoclonal antibody that works by inhibiting the signaling of the IL-4 and IL-13 pathways, according to the company. The data supporting ...

The others are atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease (COPD). Dupixent has been ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new targeted drug for the inflammatory skin disease in over a decade ...

Nemolizumab was well tolerated and provided lasting relief from itching and disease severity while improving quality of life in patients with prurigo nodularis (PN) over 68 weeks. Patients also ...

and prurigo nodularis. ATTO-3712 is in IND-enabling phase, with the company planning to start Phase I clinical studies in the second half of this year. “We will try to achieve a quarterly dosing ...

In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and ...

1 Dupilumab was previously approved in the US for treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic ...

In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment TARRYTOWN, N.Y. and PARIS, April 18 ...

chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, CSU and chronic obstructive pulmonary disease (COPD) in different age populations. More than ...

to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with prurigo nodularis under 18 years of age. with other medicines for the maintenance ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...